Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer; N. Cook; T. Arkenau; J. Melear; C. Redfern; A. I. Spira; K. Chung; T. Haddad; S. S. Ramalingam; R. Wesolowski; E. Dean; T. Goddemeier; M. Falk; G. Shapiro

doi:10.1093/annonc/mdy292.059

Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

R. Plummer, N. Cook, T. Arkenau, J. Melear, C. Redfern, A. I. Spira, K. Chung, T. Haddad, S. S. Ramalingam, R. Wesolowski, E. Dean, T. Goddemeier, M. Falk, G. Shapiro

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Pages	viii519
DOIs	https://doi.org/10.1093/annonc/mdy292.059
Publication status	Published - 1 Oct 2018

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdy292.059

Cite this

Plummer, R., Cook, N., Arkenau, T., Melear, J., Redfern, C., Spira, A. I., Chung, K., Haddad, T., Ramalingam, S. S., Wesolowski, R., Dean, E., Goddemeier, T., Falk, M., & Shapiro, G. (2018). Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC). viii519. https://doi.org/10.1093/annonc/mdy292.059

@conference{ff434498cb1c40d3a225f3dc7b529c9f,

title = "Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)",

author = "R. Plummer and N. Cook and T. Arkenau and J. Melear and C. Redfern and Spira, {A. I.} and K. Chung and T. Haddad and Ramalingam, {S. S.} and R. Wesolowski and E. Dean and T. Goddemeier and M. Falk and G. Shapiro",

year = "2018",

month = oct,

day = "1",

doi = "10.1093/annonc/mdy292.059",

language = "English",

pages = "viii519",

}

Plummer, R, Cook, N, Arkenau, T, Melear, J, Redfern, C, Spira, AI, Chung, K, Haddad, T, Ramalingam, SS, Wesolowski, R, Dean, E, Goddemeier, T, Falk, M & Shapiro, G 2018, 'Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)', pp. viii519. https://doi.org/10.1093/annonc/mdy292.059

TY - CONF

T1 - Phase I dose expansion data for M6620 (formerly VX-970), a first-in-class ATR inhibitor, combined with gemcitabine (Gem) in patients (pts) with advanced non-small cell lung cancer (NSCLC)

AU - Plummer, R.

AU - Cook, N.

AU - Arkenau, T.

AU - Melear, J.

AU - Redfern, C.

AU - Spira, A. I.

AU - Chung, K.

AU - Haddad, T.

AU - Ramalingam, S. S.

AU - Wesolowski, R.

AU - Dean, E.

AU - Goddemeier, T.

AU - Falk, M.

AU - Shapiro, G.

PY - 2018/10/1

Y1 - 2018/10/1

U2 - 10.1093/annonc/mdy292.059

DO - 10.1093/annonc/mdy292.059

M3 - Abstract

C2 - 32137346

SP - viii519

ER -